Stay updated on MBG453 Combo in IPSS-R MDS Clinical Trial
Sign up to get notified when there's something new on the MBG453 Combo in IPSS-R MDS Clinical Trial page.

Latest updates to the MBG453 Combo in IPSS-R MDS Clinical Trial page
- Check4 days agoChange DetectedRevision updated in the footer from v3.3.1 to v3.3.2. This is a minor site version update and does not affect the study information displayed.SummaryDifference0.0%

- Check11 days agoChange DetectedIn December 2023, Novartis terminated the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) failed to meet primary objectives. The termination was not due to safety concerns, and the 2025 revision added new sections such as Limitations and Caveats, Adverse Events, Outcome Measures, Baseline Characteristics, and Participant Flow.SummaryDifference0.6%

- Check19 days agoChange DetectedRemoval of a government funding/status notice from the page; no trial record content or navigation is affected.SummaryDifference0.3%

- Check33 days agoChange DetectedThe two screenshots display the same record history page with only cosmetic differences and no changes to the study data or status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedPage now includes an official operating-status notice and updates version to v3.2.0, replacing v3.1.0.SummaryDifference7%

- Check69 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.2%

Stay in the know with updates to MBG453 Combo in IPSS-R MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MBG453 Combo in IPSS-R MDS Clinical Trial page.